z-logo
open-access-imgOpen Access
Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma
Author(s) -
Stéphanie Durand-Panteix,
Jacques Monteil,
Magali Sage,
Armand Garot,
M. Clavel,
Amal Saidi,
Julien Torgue,
Michel Cogné,
Isabelle Quelven
Publication year - 2021
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-021-01585-6
Subject(s) - radioimmunotherapy , rituximab , lymphoma , medicine , biodistribution , cd20 , in vivo , spleen , cancer research , immunology , oncology , monoclonal antibody , antibody , biology , microbiology and biotechnology
Despite therapeutic advances, Non-Hodgkin lymphoma (NHL) relapses can occur. The development of radioimmunotherapy (RIT) with α-emitters is an attractive alternative. In this study, we investigated the potential of α-RIT in conjunction with 212 Pb-rituximab for the treatment of NHL.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here